Chemical Structure (Qudexy 01)
Qudexy Capsule, Extended Release
Product Images NDC 0245-1071
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Qudexy (NDC 0245-1071). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Qudexy 02)
Figure 2 (Qudexy 03)
This appears to be a chart displaying the proportion of patients in different reduction categories of seizure frequency from baseline for a placebo group and a group taking 200 mg/day of Qudexy XR. However, the chart alone may not be useful without additional context or data.*
Figure 3 (Qudexy 04)
This appears to be a table or chart with medication names and dosage information and statistical data denoted by p values. Not enough context is provided to give a full description of its content or purpose.*
Principal Display Panel (25 mg Capsule Bottle Label)
NDC 0245-1071-30 is a medication package containing 30 once-daily dosing extended-release capsules, each of which contains 25mg of topiramate. The package has instructions urging users to keep it out of reach of children and store it at controlled room temperature, as excess moisture may damage its contents. The package also contains a Medication Guide provided separately to each patient. The product is distributed by UPSHER SMITH LABORATORIES, LC.*
Principal Display Panel (50 mg Capsule Bottle Label)
Each capsule of Noc0245-1072:30 contains Topiramate 0mg and is recommended for once-daily dosing. This medication is child-resistant and should be kept out of reach of children. It should be stored in a tight container at 20-25°C, with excursions permitted to 15-30°C. The medication should be protected from moisture. Upsher-Smith Laboratories, LLC is the distributor and the product is dispensed by a pharmacist. No dosing information or indication is available in the obtained text.*
Principal Display Panel (100 mg Capsule Bottle Label)
This text provides information related to a medication called Qudexy XR, which comes in the form of extended-release capsules. It also mentions that the medication is meant to be taken once daily, and includes a warning to keep the medication out of reach of children. The pack should be stored in a tight container between 20° to 25°C (68° to 77°F), with permitted excursions of 15° to 30°C (59° to 86°F) to protect from moisture. The medication is dispensed with a medication guide for each patient, and the package contains 30 capsules that require a prescription. It also mentions that Qudexy is a registered trademark of Upsher-Smith Laboratories, LLC.*
Principal Display Panel (150 mg Capsule Bottle Label)
NDC 0245-1075-30 is a prescription drug called Qudexy° XR. It contains topiramate and is meant for once-daily dosing. The pharmacist is instructed to dispense medication gulde provided separately to each patient. It comes in a tight container and should be stored at 20° to 25°C (68° to 77°F) following USP controlled room temperature guidelines.*
Principal Display Panel (200 mg Capsule Bottle Label)
Qudexy XR is a medication used for once-daily dosing for treatment. It comes in the form of extended-release capsules in a container that should be stored between 20 to 25°C. The trademark for Qudexy is registered under Pfizer-Smith Laboratories, LLC. Additionally, a guide is provided separately to each patient.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
